Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVASE: Dornase Alfa for Hyperinflammation in COVID-19
NCT04359654Phase 2Completed
- Sponsor
- University College London
- Start
- Jun 2020
- Primary completion
- Aug 2021
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dornase alfa in coronavirus disease 2019 (COVID-19), sponsored by University College London. Started Jun 2020; status: completed.
02
Drugs
dornase alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04359654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04359654.